等待開盤 03-26 09:30:00 美东时间
+0.130
+1.86%
HC Wainwright & Co. analyst Joseph Pantginis upgrades Adlai Nortye (NASDAQ:ANL) from Neutral to Buy and announces $16 price target.
02-14 01:27
Adlai Nortye Ltd. (NASDAQ:ANL) (the "Company" or "Adlai Nortye"), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it has entered into securities
02-03 20:45
TechCreate Group Ltd. Class A涨100.1%;阿诺医药涨62.8%;罗致恒富涨27.8%
01-31 10:13
矽晶电信飙升近30%,Q4营收同比大增17%;摩丁制造大涨20%,分拆技术业务并与Gentherm合并,以优化公司结构;西南航空大涨18%,Q4每股收益及全年指引均超预期>>
01-30 18:27
Gainers Adlai Nortye (NASDAQ:ANL) stock moved upwards by 44.5% to $2.37 during...
2025-12-29 20:05
Adlai Nortye与ASK Pharm签署AN9025独家许可协议,授权其在 mainland China, Hong Kong, and Macau 开发、生产和商业化。Adlai Nortye将保留全球权利,预计获得高达16亿元人民币的总付款,包括首付款、里程碑付款及销售分成。AN9025是潜在同类最佳的pan-RAS(ON)抑制剂,针对多种肿瘤类型的RAS突变,预计2026年Q1启动I期临床试验。此次合作旨在加速RAS突变癌症患者的治疗开发。
2025-12-29 11:00
Adlai Nortye Ltd. Sponsored ADR ( ($ANL) ) has provided an announcement. Adlai ...
2025-12-03 19:27